BioLife Solutions, Inc.
NASDAQ:BLFSMedical - Instruments & Supplies
+$0.40 today
- Market cap
- $1.89B
- Beta
- 1.97
- P/E (TTM)
- -119.9
- EPS (TTM)
- -$0.22
Volume 4.39M
Average 0.52M
BLFS Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
BioLife Solutions, Inc.NASDAQ: BLFS
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 65.9% from a year ago
Cash & equivalents stood at $22.82M at the end of Q1 FY2026, down 65.9% from a year earlier and down 30.9% from the prior quarter. Over 3 fiscal years it compounded at +19.3% a year.
Context
- Cash & equivalents amounted to 5.7% of total assets at the end of Q1 FY2026, down 11.2 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -65.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 33.04M USD
- Year-over-year change
- -65.4%
- 4-year CAGR
- -17.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.04M | -65.4% |
| FY2024 | 2024-12-31 | 95.39M | +241.9% |
| FY2023 | 2023-12-31 | 27.9M | +43.5% |
| FY2022 | 2022-12-31 | 19.44M | -72.2% |
| FY2021 | 2021-12-31 | 69.87M | — |
Cash & Equivalents vs competitors
How BLFS compares with its peers on the latest reported figures
- BLFS's Mar 2026 cash & equivalents of $22.82M is the lowest of the 11 companies compared; the peer median is $116.74M.
- Its year-over-year change of -65.9% is the lowest of 11, against a peer median of +1.4%.
- Cash & equivalents amounts to 5.7% of total assets for BLFS, versus a peer median of 21.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jan 2026 | $291.32M | +436.0% | — | 76.8% | |
| Sep 2026 | $193.8M | -31.3% | -34.2% | 11.3% | |
| Aug 2026 | $172M | +23.8% | +4.4% | 5.2% | |
| Jun 2026 | $167.79M | +42.4% | +42.3% | 24.8% | |
| Apr 2026 | $131.86M | -23.8% | +21.0% | 29.2% | |
| Jun 2026 | $101.62M | -4.4% | +9.7% | 87.9% | |
| Mar 2026 | $97.32M | -23.5% | -3.6% | 12.4% | |
| Mar 2026 | $94.64M | +41.8% | -8.8% | 22.6% | |
| Sep 2026 | $75.81M | +7.3% | +4.4% | 21.1% | |
| Apr 2026 | $74.71M | -17.8% | -25.2% | 11.2% | |
| Mar 2026 | $22.82M | -65.9% | +19.3% | 5.7% | |
| Peer median (excluding BLFS) | $116.74M | +1.4% | +4.4% | 21.8% | |
Competitors are the stored peer set for BLFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 69.87M | 19.44M | 27.9M | 95.39M | 33.04M |
| Short-term Investments | 0 | 43.26M | 16.29M | 9.2M | 55.89M |
| Net Receivables | 23.22M | 33.94M | 18.66M | 9.17M | 7.95M |
| Inventory | 28.35M | 34.9M | 43.46M | 29.01M | 30.16M |
| Other Current Assets | (229K) | 6.91M | 14.31M | 6M | 9.53M |
| Total Current Assets | 125.86M | 138.45M | 120.6M | 148.76M | 136.56M |
| Property, Plant & Equipment (Net) | 36.8M | 39.2M | 32.62M | 16.76M | 22.18M |
| Goodwill | 224.74M | 224.74M | 224.74M | 212.3M | 208.59M |
| Intangible Assets | 152.15M | 32.09M | 21.15M | 9.56M | 4.26M |
| Long-term Investments | 4.37M | 6.4M | 13.33M | 5.62M | 31.25M |
| Tax Assets | (1.13M) | 0 | 21.15M | 0 | 0 |
| Other Non-current Assets | 9.81M | 9.35M | (20.88M) | 6.48M | 3.05M |
| Total Non-current Assets | 426.75M | 311.78M | 292.11M | 250.73M | 269.32M |
| Total Assets | 552.6M | 450.23M | 412.71M | 399.49M | 405.88M |
| Account Payables | 14.95M | 15.37M | 6.94M | 3.57M | 1.49M |
| Short-term Debt | 862K | 1.81M | 6.29M | 10.94M | 5M |
| Tax Payables | 27K | 5.13M | 6M | 4.26M | 0 |
| Deferred Revenue | 814K | 548K | 661K | 103K | 195K |
| Other Current Liabilities | 21.52M | 20.71M | 23.21M | 5.23M | 5.93M |
| Total Current Liabilities | 42.7M | 44.58M | 42.18M | 32.73M | 22.98M |
| Long-term Debt | 6.35M | 23.79M | 17.56M | 5M | 0 |
| Deferred Tax Liabilities | 5.49M | 250K | 114K | 124K | 189K |
| Deferred Revenue (Non-current) | (1.66M) | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 4.94M | 2.33M | 6.5M | 78K | 171K |
| Total Non-current Liabilities | 33.54M | 41.46M | 32.87M | 17.84M | 11.02M |
| Total Liabilities | 76.24M | 86.04M | 75.05M | 50.58M | 34M |
| Common Stock | 42K | 43K | 45K | 47K | 48K |
| Retained Earnings | (105.02M) | (246.92M) | (313.34M) | (335.1M) | (339.7M) |
| Accumulated OCI | (282K) | (679K) | (345K) | 24K | 132K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 480.75M | 364.19M | 337.66M | 348.91M | 371.89M |
| Total Debt | 26.88M | 43.71M | 33.83M | 30.17M | 17.9M |
| Net Debt | (42.99M) | 24.27M | 5.93M | (65.21M) | (15.14M) |
BioLife Solutions, Inc.
NASDAQ:BLFS
Intrinsic Alpha fair value
Locked
Current Price
$38.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.